THE CHARACTERISTICS OF MIRNA BINDING SITES IN MRNA OF ZFHX3 GENE AND ITS ORTHOLOGS

Transcription factor gene ZFHX3 is one of the candidate genes involved in stroke development. The ZFHX3 protein contains oligopeptides encoded by trinucleotide repeats (TNRs). TNR variability is considered to be one of the causes of the disease, but their biological function has not yet been established. We assume that TNRs are the binding sites of miRNA to mRNA and are involved in regulation of ZFHX3 gene expression. The characteristics of miRNA–mRNA interaction were determined using MirTarget software. It has been shown that the first TNR in mRNA of the human ZFHX3 gene consists of the seven consecutive miR-12-32603-3p binding encoding polyGlu. The ZFHX3 protein of human polyGlu contains 30 Glu. In the orthologous proteins of 36 animal species the length of polyGlu varied from 27 Glu to 33 Glu. Negatively charged polyGlu of the ZFHX3 transcription factor probably interacted with positive DNA-binding proteins. The following mRNA region of the ZFHX3 gene contained the binding sites for miR-17-39416-3p, miR-5-15733-3p, miR-9-20317-3 encoding polyAla by 15 Ala lengths. In the 33 ZFHX3 orthologous proteins polyAla had the same length. The mRNA region of the human ZFHX3 gene with binding polysite of miR-1322-3p encoded polyGln consisting of 19 Gln. In the 41 orthologs of the ZFHX3 protein the length of polyGln varied from seven Gln to 23 Gln. The binding sites of miR-2-6184-3p, miR-5-14114-5p and miR-19-43437-5p were located with overlapping nucleotides sequences, and encode polyPro. In ZFHX3 human polyPro consisted of 12 Pro. In the orthologs, polyPro contained from 10 Pro to 14 Pro. The binding sites of miR-17-39416-3p, miR-9-20317-3p, miR-1-1819-3p, miR-5-15733-3p, miR-6-17815-3p, miR-18-39953-5p, miR-26862-5p, miR-1260b and miR-X-48174-3p in human ZFHX3 encoded polyGly by 22 Gly length. In the 28 orthologs of ZFHX3 the length of polyGly decreased to 11 Gly. The TNR regions could simultaneously bind several miRNAs, which increased the dependence of gene expression on miRNA. The oligopeptides encoded by the binding polysites of miRNA in mRNA in the orthologous ZFHX3 proteins were flanked by conserved oligopeptides

NON-MOTOR VISUAL DISORDERS IN KAZAKHTAN PATIENTS WITH PARKINSON'S DISEASE

We observed 106 Parkinson’s patients in Almaty city to detect non-motor visual disorders. Among non-motor symptoms in patients with Parkinson’s disease (PD), visual symptoms are becoming increasingly important. Visual impairments cause severe disability, reduce compensatory ability and adaptation of the patient to motor impairments and reduce life expectancy. Many neurologists do not take into serious consideration the importance of visual disorders in PD. This type of research has never been carried out in Kazakhstan or indeed the rest of Central Asia. To study visual non-motor disorders in PD patients in Almaty to help optimize diagnosis and evaluate their correlation with disease duration and severity.  The diagnosis included the following elements: patient’s complaints and history, a general physical examination, a neurological examination with auxiliary assessment scales. The study confirmed that non-motor manifestations are common in PD patients. Research to date has confirmed the predictive value of non-motor PD manifestations. Non-motor visual impairments are important to the overall quality of life of Parkinson’s patients as well its motor manifestation, and require a very careful approach and considerable effort for early detection by a physician, medical personnel and caregivers, including relatives

NON-MOTOR VISUAL DISORDERS IN KAZAKHTAN PATIENTS WITH PARKINSON'S DISEASE

We observed 106 Parkinson’s patients in Almaty city to detect non-motor visual disorders. Among non-motor symptoms in patients with Parkinson’s disease (PD), visual symptoms are becoming increasingly important. Visual impairments cause severe disability, reduce compensatory ability and adaptation of the patient to motor impairments and reduce life expectancy. Many neurologists do not take into serious consideration the importance of visual disorders in PD. This type of research has never been carried out in Kazakhstan or indeed the rest of Central Asia. To study visual non-motor disorders in PD patients in Almaty to help optimize diagnosis and evaluate their correlation with disease duration and severity.  The diagnosis included the following elements: patient’s complaints and history, a general physical examination, a neurological examination with auxiliary assessment scales. The study confirmed that non-motor manifestations are common in PD patients. Research to date has confirmed the predictive value of non-motor PD manifestations. Non-motor visual impairments are important to the overall quality of life of Parkinson’s patients as well its motor manifestation, and require a very careful approach and considerable effort for early detection by a physician, medical personnel and caregivers, including relatives

CLINICAL FEATURES AND REASONS FOR THE PROGRESSION OF ISCHEMIC STROKE IN THE ACUTE PERIOD

We examined 663 patients who were admitted to the clinic by ambulance, for determine the factors of clinical deterioration and progression of ischemic stroke in the acute period of the first 24-72 hours. Among the patients received in the acute period, a fatal out come occurred in 7.23% (48) patients, men- 45.8% and women - 54.2%.At the time of admission to the hospital, almost 96.7% of patients with acute ischemic stroke had a disorder of consciousness from stunning to coma. The most significant risk factors for the development of ischemic stroke among 663 patients were arterial hypertension - 80.1%, chronic heartfailure - 57.9%, coronary heart disease - 25.5%, atrial fibrillation - 19.5%, type 2 diabetesmellitus 12.5%. In accordance with the international criteria of TOAST (1993), pathogenetic mechanisms of the development of isch- emic stroke have been determined in patients. Atherothrombotic stroke developed in 303 (45.7%), cardioembolic stroke in 185 (27.9%) patients, lacunar stroke in 167 (25.2%) patients, undefined genesis stroke in 8 (1.2%) patients.The progression of neurological deficiency in ischemic stroke is a bad prognostic factor

CLINICAL FEATURES AND REASONS FOR THE PROGRESSION OF ISCHEMIC STROKE IN THE ACUTE PERIOD

We examined 663 patients who were admitted to the clinic by ambulance, for determine the factors of clinical deterioration and progression of ischemic stroke in the acute period of the first 24-72 hours. Among the patients received in the acute period, a fatal out come occurred in 7.23% (48) patients, men- 45.8% and women - 54.2%.At the time of admission to the hospital, almost 96.7% of patients with acute ischemic stroke had a disorder of consciousness from stunning to coma. The most significant risk factors for the development of ischemic stroke among 663 patients were arterial hypertension - 80.1%, chronic heartfailure - 57.9%, coronary heart disease - 25.5%, atrial fibrillation - 19.5%, type 2 diabetesmellitus 12.5%. In accordance with the international criteria of TOAST (1993), pathogenetic mechanisms of the development of isch- emic stroke have been determined in patients. Atherothrombotic stroke developed in 303 (45.7%), cardioembolic stroke in 185 (27.9%) patients, lacunar stroke in 167 (25.2%) patients, undefined genesis stroke in 8 (1.2%) patients.The progression of neurological deficiency in ischemic stroke is a bad prognostic factor

Microsoft Office Graphics Technologies and VBA Programming

В статье рассмотрены графические возможности пакета Microsoft Office. Рассмотрены стандартные возможности встроенных средств рисования и редактирования изображений. Отдельно рассмотрены нестандартные приемы рисования в программах Excel, Word, OneNote, а также технологии офисного программирования в образовательном процессе. В данной статье рассматриваются как стандартные методы создания и редактирования изображений средствами Microsoft Office, так и нестандартные, непредусмотренные производителем приёмы рисования с использованием данного пакета. Обсуждаются актуальные вопросы современного медиаобразования в контексте формирования алгоритмического мышления и интеллектуальных умений. Отмечено, что при реализации определенного алгоритма на языке VBA, использование модулей и макросов, графических иллюстраций помогает преподавателю формировать умение принимать решения, анализировать проблемные ситуации, заставляет глубже исследовать особенности офисных технологий в разработке прикладных программ. Возможно гибкое планирование индивидуальных образовательных маршрутов в зависимости от обучающих целей и дидактических задач в плане применения интерактивной компьютерной графики в выбранной парадигме программирования.The article discusses the graphical capabilities of the Microsoft Office suite. The standard capabilities of the built-in drawing and image editing tools are considered. Non-standard drawing techniques in Excel, Word, OneNote programs, as well as office programming technologies in the educational process are considered separately. Topical issues of modern media education in the context of the formation of algorithmic thinking and intellectual skills are discussed. It is noted that when implementing a certain algorithm in the VBA language, the use of modules and macros, graphic illustrations helps the teacher to form the ability to make decisions, analyze problem situations, makes it deeper to explore the features of office technologies in the development of application programs. Flexible planning of individual educational routes is possible, depending on the learning goals and didactic tasks in terms of the use of interactive computer graphics in the chosen programming paradigm

Primary stroke prevention worldwide : translating evidence into action

Funding Information: The stroke services survey reported in this publication was partly supported by World Stroke Organization and Auckland University of Technology. VLF was partly supported by the grants received from the Health Research Council of New Zealand. MOO was supported by the US National Institutes of Health (SIREN U54 HG007479) under the H3Africa initiative and SIBS Genomics (R01NS107900, R01NS107900-02S1, R01NS115944-01, 3U24HG009780-03S5, and 1R01NS114045-01), Sub-Saharan Africa Conference on Stroke Conference (1R13NS115395-01A1), and Training Africans to Lead and Execute Neurological Trials & Studies (D43TW012030). AGT was supported by the Australian National Health and Medical Research Council. SLG was supported by a National Heart Foundation of Australia Future Leader Fellowship and an Australian National Health and Medical Research Council synergy grant. We thank Anita Arsovska (University Clinic of Neurology, Skopje, North Macedonia), Manoj Bohara (HAMS Hospital, Kathmandu, Nepal), Denis ?erimagi? (Poliklinika Glavi?, Dubrovnik, Croatia), Manuel Correia (Hospital de Santo Ant?nio, Porto, Portugal), Daissy Liliana Mora Cuervo (Hospital Moinhos de Vento, Porto Alegre, Brazil), Anna Cz?onkowska (Institute of Psychiatry and Neurology, Warsaw, Poland), Gloria Ekeng (Stroke Care International, Dartford, UK), Jo?o Sargento-Freitas (Centro Hospitalar e Universit?rio de Coimbra, Coimbra, Portugal), Yuriy Flomin (MC Universal Clinic Oberig, Kyiv, Ukraine), Mehari Gebreyohanns (UT Southwestern Medical Centre, Dallas, TX, USA), Ivete Pillo Gon?alves (Hospital S?o Jos? do Avai, Itaperuna, Brazil), Claiborne Johnston (Dell Medical School, University of Texas, Austin, TX, USA), Kristaps Jurj?ns (P Stradins Clinical University Hospital, Riga, Latvia), Rizwan Kalani (University of Washington, Seattle, WA, USA), Grzegorz Kozera (Medical University of Gda?sk, Gda?sk, Poland), Kursad Kutluk (Dokuz Eylul University, ?zmir, Turkey), Branko Malojcic (University Hospital Centre Zagreb, Zagreb, Croatia), Micha? Maluchnik (Ministry of Health, Warsaw, Poland), Evija Migl?ne (P Stradins Clinical University Hospital, Riga, Latvia), Cassandra Ocampo (University of Botswana, Princess Marina Hospital, Botswana), Louise Shaw (Royal United Hospitals Bath NHS Foundation Trust, Bath, UK), Lekhjung Thapa (Upendra Devkota Memorial-National Institute of Neurological and Allied Sciences, Kathmandu, Nepal), Bogdan Wojtyniak (National Institute of Public Health, Warsaw, Poland), Jie Yang (First Affiliated Hospital of Chengdu Medical College, Chengdu, China), and Tomasz Zdrojewski (Medical University of Gda?sk, Gda?sk, Poland) for their comments on early draft of the manuscript. The views expressed in this article are solely the responsibility of the authors and they do not necessarily reflect the views, decisions, or policies of the institution with which they are affiliated. We thank WSO for funding. The funder had no role in the design, data collection, analysis and interpretation of the study results, writing of the report, or the decision to submit the study results for publication. Funding Information: The stroke services survey reported in this publication was partly supported by World Stroke Organization and Auckland University of Technology. VLF was partly supported by the grants received from the Health Research Council of New Zealand. MOO was supported by the US National Institutes of Health (SIREN U54 HG007479) under the H3Africa initiative and SIBS Genomics (R01NS107900, R01NS107900-02S1, R01NS115944-01, 3U24HG009780-03S5, and 1R01NS114045-01), Sub-Saharan Africa Conference on Stroke Conference (1R13NS115395-01A1), and Training Africans to Lead and Execute Neurological Trials & Studies (D43TW012030). AGT was supported by the Australian National Health and Medical Research Council. SLG was supported by a National Heart Foundation of Australia Future Leader Fellowship and an Australian National Health and Medical Research Council synergy grant. We thank Anita Arsovska (University Clinic of Neurology, Skopje, North Macedonia), Manoj Bohara (HAMS Hospital, Kathmandu, Nepal), Denis Čerimagić (Poliklinika Glavić, Dubrovnik, Croatia), Manuel Correia (Hospital de Santo António, Porto, Portugal), Daissy Liliana Mora Cuervo (Hospital Moinhos de Vento, Porto Alegre, Brazil), Anna Członkowska (Institute of Psychiatry and Neurology, Warsaw, Poland), Gloria Ekeng (Stroke Care International, Dartford, UK), João Sargento-Freitas (Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal), Yuriy Flomin (MC Universal Clinic Oberig, Kyiv, Ukraine), Mehari Gebreyohanns (UT Southwestern Medical Centre, Dallas, TX, USA), Ivete Pillo Gonçalves (Hospital São José do Avai, Itaperuna, Brazil), Claiborne Johnston (Dell Medical School, University of Texas, Austin, TX, USA), Kristaps Jurjāns (P Stradins Clinical University Hospital, Riga, Latvia), Rizwan Kalani (University of Washington, Seattle, WA, USA), Grzegorz Kozera (Medical University of Gdańsk, Gdańsk, Poland), Kursad Kutluk (Dokuz Eylul University, İzmir, Turkey), Branko Malojcic (University Hospital Centre Zagreb, Zagreb, Croatia), Michał Maluchnik (Ministry of Health, Warsaw, Poland), Evija Miglāne (P Stradins Clinical University Hospital, Riga, Latvia), Cassandra Ocampo (University of Botswana, Princess Marina Hospital, Botswana), Louise Shaw (Royal United Hospitals Bath NHS Foundation Trust, Bath, UK), Lekhjung Thapa (Upendra Devkota Memorial-National Institute of Neurological and Allied Sciences, Kathmandu, Nepal), Bogdan Wojtyniak (National Institute of Public Health, Warsaw, Poland), Jie Yang (First Affiliated Hospital of Chengdu Medical College, Chengdu, China), and Tomasz Zdrojewski (Medical University of Gdańsk, Gdańsk, Poland) for their comments on early draft of the manuscript. The views expressed in this article are solely the responsibility of the authors and they do not necessarily reflect the views, decisions, or policies of the institution with which they are affiliated. We thank WSO for funding. The funder had no role in the design, data collection, analysis and interpretation of the study results, writing of the report, or the decision to submit the study results for publication. Funding Information: VLF declares that the PreventS web app and Stroke Riskometer app are owned and copyrighted by Auckland University of Technology; has received grants from the Brain Research New Zealand Centre of Research Excellence (16/STH/36), Australian National Health and Medical Research Council (NHMRC; APP1182071), and World Stroke Organization (WSO); is an executive committee member of WSO, honorary medical director of Stroke Central New Zealand, and CEO of New Zealand Stroke Education charitable Trust. AGT declares funding from NHMRC (GNT1042600, GNT1122455, GNT1171966, GNT1143155, and GNT1182017), Stroke Foundation Australia (SG1807), and Heart Foundation Australia (VG102282); and board membership of the Stroke Foundation (Australia). SLG is funded by the National Health Foundation of Australia (Future Leader Fellowship 102061) and NHMRC (GNT1182071, GNT1143155, and GNT1128373). RM is supported by the Implementation Research Network in Stroke Care Quality of the European Cooperation in Science and Technology (project CA18118) and by the IRIS-TEPUS project from the inter-excellence inter-cost programme of the Ministry of Education, Youth and Sports of the Czech Republic (project LTC20051). BN declares receiving fees for data management committee work for SOCRATES and THALES trials for AstraZeneca and fees for data management committee work for NAVIGATE-ESUS trial from Bayer. All other authors declare no competing interests. Publisher Copyright: © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseStroke is the second leading cause of death and the third leading cause of disability worldwide and its burden is increasing rapidly in low-income and middle-income countries, many of which are unable to face the challenges it imposes. In this Health Policy paper on primary stroke prevention, we provide an overview of the current situation regarding primary prevention services, estimate the cost of stroke and stroke prevention, and identify deficiencies in existing guidelines and gaps in primary prevention. We also offer a set of pragmatic solutions for implementation of primary stroke prevention, with an emphasis on the role of governments and population-wide strategies, including task-shifting and sharing and health system re-engineering. Implementation of primary stroke prevention involves patients, health professionals, funders, policy makers, implementation partners, and the entire population along the life course.publishersversionPeer reviewe

Observation of the Decay Λ0b→Λ+cτ−¯ν

The first observation of the semileptonic b-baryon decay Λb0→Λc+τ-ν¯τ, with a significance of 6.1σ, is reported using a data sample corresponding to 3 fb-1 of integrated luminosity, collected by the LHCb experiment at center-of-mass energies of 7 and 8 TeV at the LHC. The τ- lepton is reconstructed in the hadronic decay to three charged pions. The ratio K=B(Λb0→Λc+τ-ν¯τ)/B(Λb0→Λc+π-π+π-) is measured to be 2.46±0.27±0.40, where the first uncertainty is statistical and the second systematic. The branching fraction B(Λb0→Λc+τ-ν¯τ)=(1.50±0.16±0.25±0.23)% is obtained, where the third uncertainty is from the external branching fraction of the normalization channel Λb0→Λc+π-π+π-. The ratio of semileptonic branching fractions R(Λc+)B(Λb0→Λc+τ-ν¯τ)/B(Λb0→Λc+μ-ν¯μ) is derived to be 0.242±0.026±0.040±0.059, where the external branching fraction uncertainty from the channel Λb0→Λc+μ-ν¯μ contributes to the last term. This result is in agreement with the standard model prediction

Observation of the doubly charmed baryon decay Ξcc++→Ξc′+π+

The Ξcc++→Ξc′+π+ decay is observed using proton-proton collisions collected by the LHCb experiment at a centre-of-mass energy of 13 TeV, corresponding to an integrated luminosity of 5.4 fb−1. The Ξcc++→Ξc′+π+ decay is reconstructed partially, where the photon from the Ξc′+→Ξc+γ decay is not reconstructed and the pK−π+ final state of the Ξc+ baryon is employed. The Ξcc++→Ξc′+π+branching fraction relative to that of the Ξcc++→Ξc+π+ decay is measured to be 1.41 ± 0.17 ± 0.10, where the first uncertainty is statistical and the second systematic. [Figure not available: see fulltext.

Study of charmonium and charmonium-like contributions in B+ → J/ψηK+ decays

A study of B+→ J/ψηK+ decays, followed by J/ψ → μ+μ− and η → γγ, is performed using a dataset collected with the LHCb detector in proton-proton collisions at centre-of-mass energies of 7, 8 and 13 TeV, corresponding to an integrated luminosity of 9 fb−1. The J/ψη mass spectrum is investigated for contributions from charmonia and charmonium-like states. Evidence is found for the B+→ (ψ2(3823) → J/ψη)K+ and B+→ (ψ(4040) → J/ψη)K+ decays with significance of 3.4 and 4.7 standard deviations, respectively. This constitutes the first evidence for the ψ2(3823) → J/ψη decay